AstraZeneca PLC has released its final results for the fiscal year (FY) 2025, showcasing strong commercial performance and pipeline delivery. Here’s a summary of the key highlights
### **Financial Performance**
**Total Revenue**Increased by 8% to $58,739 million, driven by growth in Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Disease segments.
**Core EPS**: Grew by 11% to $9.16with Reported EPS at $6.60.
**Dividends**Second interim dividend declared at $2.17 per share, with a total FY 2025 dividend of $3.20 per share, up 3%.
### **Pipeline and Regulatory Milestones**
**Phase 3 Readouts**16 positive Phase 3 readouts in the last 12 months.
**Approvals**43 approvals in major regions, including Enhertu, Imfinzi, and Saphnelo.
**Ongoing Trials**Over 100 Phase 3 studies, including transformative technologies with potential to revolutionize patient outcomes.
### **Strategic Developments**
**NYSE Listing**Ordinary shares began trading on the NYSE on February 2, 2026, harmonizing listings across London, New York, and Stockholm.
**China Investment**Announced $15 billion investment in China through 2030 for manufacturing and R&D expansion.
**Acquisitions and Collaborations**
Acquired Modella AI to enhance oncology R&D with AI.
Strategic collaboration with CSPC Pharmaceuticals for weight management portfolio.
Acquired AbelZeta’s 50% share in C-CAR031 for global development.
### **Sustainability**
Recognized by CDP for climate action and water stewardship, with an A for Climate and A- for Water Security.
Launched PSA 2090, a global standard to measure environmental impact of pharmaceutical products.
### **Guidance for FY 2026**
**Total Revenue**Expected to increase by mid-to-high single-digit percentage.
**Core EPS**Expected to increase by a low double-digit percentage.
**Core Tax Rate**Projected between 18-22%.
### **Key Medicines Performance**
**Oncology**: TagrissoImfinziand Enhertu showed strong growth.
**CVRM**: Farxiga led growthdriven by HF and CKD indications.
**R&I**Fasenra and Tezspire demonstrated sustained demand growth.
**Rare Disease**Ultomiris and Soliris saw growth, with Soliris declining due to patient conversion to Ultomiris.
### **Corporate and Business Development**
**Jacobio Pharma**Exclusive rights for JAB-23E73 outside China.
**BMS**Paid $170 million to reduce royalties on Saphnelo sales ex-US.
**Compugen**Paid $65 million for a portion of royalty interest in rilvegostomig.
### **Sustainability and Health Equity**
Expanded Healthy Heart Africa program to include CKD screening in multiple African countries.
Committed to China’s rare disease ecosystem and global health equity initiatives.
### **Outlook**
AstraZeneca anticipates continued momentum in 2026, with over 20 Phase 3 trial readouts expected. The company remains focused on transformative technologies and sustainable growth, aiming to drive long-term value for patients and shareholders.
For more details, refer to the full report on the London Stock Exchanges RNS platform.
Here is the comparison of financials and debt year on year presented as an HTML table:
**Key Observations:** - **Revenue Growth:** Total revenue increased by 9% from FY 2024 to FY 2025, driven primarily by a 10% increase in Product Revenue and a 39% increase in Alliance Revenue.
- **EPS Growth:** Reported EPS increased significantly by 45%, while Core EPS grew by 12%, reflecting strong operational performance.
- **Debt Reduction:** Net debt decreased by 5%, indicating improved financial health and debt management. This table provides a concise comparison of key financial metrics and debt levels between FY 2024 and FY 2025.
